Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study
Viruses · 21.04.2026 · 18 (4) · 479
DOI: 10.3390/v18040479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 21.04.2026. Verfasst von Yuichiro Shindo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Alanine, Antiviral Agents, Adenosine Monophosphate. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, K.K, Gilead Sciences, K.K..
Abstract (Originalsprache)
Early initiation of remdesivir (RDV) is recommended to improve COVID-19 outcomes, but real-world studies describing patterns of RDV use and related outcomes among Japanese COVID-19 patients at high-risk of severe outcomes or death are limited. This claims-based cohort study included 60,165 high-risk patients hospitalized with COVID-19 between October 2021 and June 2023 using the DeSC Healthcare claims database. Patients were categorized into early-RDV (within 2 days of hospital admission), late-RDV (between day 3 and day 7), and no-RDV groups based on RDV initiation timing. Descriptive analyses were performed according to RDV groups. Of the study patients, ≥85% were very elderly (≥75 years). Approximately 39% of patients received early RDV, 2% received late RDV, and 59% received no RDV. By day 28, the proportion of alive discharge for early-, late-, and no-RDV groups was 74.9%, 63.1%, and 71.8%, respectively. The mortality for early-, late-, and no-RDV groups was 7.7%, 8.8%, and 8.4%, respectively. Future hypothesis-driven studies with an appropriate adjustment for confounders are needed to formally evaluate the impact of RDV initiation timing on clinical outcomes in this high-risk, predominantly late-elderly population in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
- Gilead Sciences, K.K., 16/F GRAN TOKYO SOUTH TOWER, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan.
- Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94405, USA.
- Gilead Sciences, EU, 2 Roundwood Ave., Uxbridge UB11 1AF, UK.
ORCID-Profile: Yuichiro Shindo, Mark Berry
Förderung
- Gilead Sciences, K.K
- Gilead Sciences, K.K.
Zitieren
APA
Shindo, Y., Piao, Y., Berry, M., Ramroth, H., & Yoshida, M. (2026). Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study. Viruses, 18(4), 479. https://doi.org/10.3390/v18040479
Vancouver
Shindo Y, Piao Y, Berry M, Ramroth H, Yoshida M. Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study. Viruses. 2026;18(4):479. doi:10.3390/v18040479
BibTeX
@article{Shindo2026,
author = {Shindo, Yuichiro and Piao, Yi and Berry, Mark and Ramroth, Heribert and Yoshida, Manami},
title = {Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study},
journal = {Viruses},
year = {2026},
volume = {18},
number = {4},
pages = {479},
doi = {10.3390/v18040479}
}
EUVIMED